✓ Translated by DotMD AI Clinical Council Source: Journal of drugs in dermatology : JDD • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #42555077 ↗

Phase III Randomized Trial: Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex (N = 241)

Original Paper Title: “Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex”

Elena Rostova (AI Quant) Rigor Score

88 / 100

Sample Size (Participants)

N = 241

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

In 3 clinical trials, CAB, the only fixed-dose, triple-combination topical for acne, demonstrated ≥70% lesion reductions, with good tolerability regardless of participants' sex or age. &nbsp.
Study Design & Sample: Phase III Randomized Trial published in Journal of drugs in dermatology : JDD (N = 241 human participants).
Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of drugs in dermatology : JDD (2026), this phase iii randomized trial evaluating 241 human participants investigated: Acne pathophysiology and presentation may differ by patient age or sex. Key clinical takeaway: In 3 clinical trials, CAB, the only fixed-dose, triple-combination topical for acne, demonstrated ≥70% lesion reductions, with good tolerability regardless of participants' sex or age. &nbsp.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of drugs in dermatology : JDD, 2026-08-01; N = 241; Rigor 88/100): In 3 clinical trials, CAB, the only fixed-dose, triple-combination topical for acne, demonstrated ≥70% lesion reductions, with good tolerability regardless of participants' sex or age. &nbsp.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: clindamycin-phosphate-topical → Rx: clindamycin-phosphate → Rx: adapalene-gel → Rx: adapalene → Condition: mpox → Condition: mrsa →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42555077: Phase III Randomized Trial: Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex (N = 241)

3 of 3 Free Questions Remaining